Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

Update: 2025-12-03

Description

Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance of comprehensive molecular testing, the World Health Organization classification of tumors of the central nervous system, and newly available therapies.

Comments

In Channel

Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

2025-12-0313:47

Maturing with Migraine: Practical Guidelines for Transitioning Adolescent Migraine and Headache Patients into Adult Practice

2025-12-0223:51

Advances in ALS: New Targets, Trials, and Care Strategies

2025-10-2714:57

Cerebrovascular Inflammatory Conditions: Diagnostic Challenges and Treatment Considerations

2025-10-2219:03

The Evolving Therapeutic Landscape for Parkinson Disease

2025-06-0620:39

Advances in the Evaluation of TBI

2024-06-0420:44

NMOSD Part 3 - Overview of treatment, including goals, triggers, and considerations for switching therapies

2024-02-2920:14

NMOSD Part 2 - The importance and tools for monitoring NMOSD, and signs, symptoms and evaluation of disease activity

2024-02-1522:53

NMOSD Part 1 - Overview and important considerations for diagnosis

2024-02-0131:51

Narcolepsy, Idiopathic Hypersomnia, and General Sleep Disorders

2023-12-0527:38

00:00

1.0x

Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

#box-pro-ellipsis-176501577362993{-webkit-line-clamp:2;}Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies

Practical Neurology

Modern Glioma Management: Integrating Molecular Markers and New Targeted Therapies